Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 25:13:1011810.
doi: 10.3389/fonc.2023.1011810. eCollection 2023.

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Yurong Peng  1 , Zhuo Li  2 , Yucheng Fu  1 , Yue Pan  1 , Yue Zeng  1 , Junqi Liu  1 , Chaoyue Xiao  1 , Yingzhe Zhang  1 , Yahui Su  3 , Guoqing Li  3 , Fang Wu  1
Affiliations
Review

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Yurong Peng et al. Front Oncol. .

Erratum in

Abstract

Lung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments. Curative surgery for patients with early-stage lung cancer is the standard of care, but not all surgical treatments have a good prognosis. Adjuvant and neoadjuvant chemotherapy are used to improve the prognosis of patients with resectable lung cancer. Immunotherapy, an epoch-defining treatment, has improved curative effects, prognosis, and tolerability compared with traditional and ordinary cytotoxic chemotherapy, providing new hope for patients with non-small cell lung cancer (NSCLC). Immunotherapy-related clinical trials have reported encouraging clinical outcomes in their exploration of different types of perioperative immunotherapy, from neoadjuvant immune checkpoint inhibitor (ICI) monotherapy, neoadjuvant immune-combination therapy (chemoimmunotherapy, immunotherapy plus antiangiogenic therapy, immunotherapy plus radiotherapy, or concurrent chemoradiotherapy), adjuvant immunotherapy, and neoadjuvant combined adjuvant immunotherapy. Phase 3 studies such as IMpower 010 and CheckMate 816 reported survival benefits of perioperative immunotherapy for operable patients. This review summarizes up-to-date clinical studies and analyzes the efficiency and feasibility of different neoadjuvant therapies and biomarkers to identify optimal types of perioperative immunotherapy for NSCLC.

Keywords: NSCLC; adjuvant therapy; biomarkers; immunotherapy; lung cancer; neoadjuvant immune monotherapy; neoadjuvant therapies; perioperative period perioperative immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Biomarkers of perioperative immunotherapy. TME, Tumor microenvironment. IL-8, interleukin-8. TGF-β, Transforming growth factor. IL-6, interleukin-6. ILT-2, Ig-like transcript 2. TLS, Tertiary lymphoid structures. TIL, tumor-infiltrating lymphocytes. EGFR, epidermal growth factor receptor. HLA, human leukocyte antigen. PD-1, programmed cell death protein 1. PD-L1, Programmed cell death ligand 1. HRD, Homologous recombination deficiency. DDR, DNA-damage response/HR, homologous recombination pathway, MMR, mismatch repair. MSI, microsatellite instability. TMB, tumor mutation burden. KMT2A/B/C, Lysine methyltransferase 2A/B/C. POLE, polymerase epsilon. DNMT3A, DNA methyltransferases 3A. BMI, body mass index. CEA, carcinoembryonic antigen. NK, natural killer cells. AKK, Akkermansia muciniphila. NK, natural killer cells. CD4, cluster of differentiation 4. CD8+, cluster of differentiation 8. Treg, regulatory T cells. DC, dendritic cells. CTL, cytotoxic T lymphocyte.
Figure 2
Figure 2
The Phase III clinical trials of different modes of perioperative immunotherapy for Non-Small Cell Lung Cancer. CT, chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin (2022) 72(1):7–33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc (2008) 83(5):584–94. doi: 10.4065/83.5.584 - DOI - PMC - PubMed
    1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. . The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2016) 11(1):39–51. doi: 10.1016/j.jtho.2015.09.009 - DOI - PubMed
    1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med (2004) 350(4):351–60. doi: 10.1056/NEJMoa031644 - DOI - PubMed
    1. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New Engl J Med (2005) 352(25):2589–97. doi: 10.1056/NEJMoa043623 - DOI - PubMed